Oncovita presents promising preclinical data on MVdeltaC, a novel onco-immunotherapy at EACR, 8-11 June 2026, in BudapestThe full preclinical pharmacology package includes results from many solid tumors models including mesothelioma, bladder, triple negative breast cancer (TNBC) and neuroblastoma and the demonstration of the mechanism of action inducing enhanced immunogenic cancer cell death and reactivation of cold tumors.
Oncovita announces a strategic partnership with Infinitusbio.AI to explore the design and optimize the development of new therapeutic candidates from its Measovir® platform.Oncovita announces a strategic partnership with Infinitusbio.AI to explore the design and optimize the development of new therapeutic candidates from its Measovir® platform.
Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinologyOncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology
Oncovita Won a Financing of €4,5M From Bpifrance and Raised €3,5M From Private Investors and Business Angels
Oncovita, winner of the "Innovations in biotherapies and biomanufacturing" call for projects, will benefit from €4.5 million in funding under the France 2030 investment plan, and has completed a €3.5 million round of financing from private investors to support the development of its MVdeltaC immunotherapeutic vaccine in oncology.
